Stock Image

Novel Developments in Stem Cell Mobilization

Stefan Fruehauf

0 ratings by GoodReads
ISBN 10: 146141959X / ISBN 13: 9781461419594
Published by Springer-Verlag Gmbh Feb 2012, 2012
New Condition: Neu Buch
From Agrios-Buch (Bergisch Gladbach, Germany)

AbeBooks Seller Since 11 January 2012

Seller Rating 5-star rating

Quantity Available: 1

Available from more sellers

View all  copies of this book
Buy New
Price: 209.11 Convert Currency
Shipping: 8.58 From Germany to United Kingdom Destination, Rates & Speeds
Add to basket

Payment Methods
accepted by seller

Visa Mastercard American Express

Check PayPal Invoice Bank/Wire Transfer

About this Item

Neuware - Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented. 496 pp. Englisch. Bookseller Inventory # 9781461419594

Ask Seller a Question

Bibliographic Details

Title: Novel Developments in Stem Cell Mobilization

Publisher: Springer-Verlag Gmbh Feb 2012

Publication Date: 2012

Binding: Buch

Book Condition:Neu

About this title

Synopsis:

Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.

"About this title" may belong to another edition of this title.